Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TQB3702 in Healthy Adults
NCT06448273Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing TQB3702 with Placebo (2 arms). Primary endpoints: Adverse events rate at 17 days and Abnormal laboratory test indicators at 17 days. Started Jul 2024; status: recruiting.
02
Drugs
TQB3702
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06448273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448273.